Neuland Laboratories Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Neuland Laboratories Ltd is ₹ 17177 as of 12 Jun 15:30 . The P/E Ratio of Neuland Laboratories Ltd changed from 33.4 on March 2021 to 59.9 on March 2025 . This represents a CAGR of 12.39% over 5 yearsThe P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Neuland Laboratories Ltd changed from ₹ 2678 crore on March 2021 to ₹ 15494 crore on March 2025 . This represents a CAGR of 42.05% over 5 yearsThe Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Neuland Laboratories Ltd for the Mar '26 is ₹ 788.71 crore as compare to the Dec '25 revenue of ₹ 447.76 crore. This represent the growth of 76.15% The revenue of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 192.86 crore as compare to the Dec '25 revenue of ₹ 178.34 crore. This represent the growth of 8.14% The ebitda of Neuland Laboratories Ltd for the Mar '26 is ₹ 319.79 crore as compare to the Dec '25 ebitda of ₹ 85.19 crore. This represent the growth of 275.38% The ebitda of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 65.16 crore as compare to the Dec '25 ebitda of ₹ 57.79 crore. This represent the growth of 12.75% The net profit of Neuland Laboratories Ltd changed from ₹ 97.87 crore to ₹ 212.67 crore over 8 quarters. This represents a CAGR of 47.41% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 10.91 crore to ₹ 36.67 crore over 8 quarters. This represents a CAGR of 83.33% The Dividend Payout of Neuland Laboratories Ltd changed from 8.03 % on March 2021 to 5.97 % on March 2025 . This represents a CAGR of -5.76% over 5 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Neuland Laboratories Ltd

Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao.
The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin.
Neuland Drugs & Pharmaceuticals Pvt.
Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992.
NLL manufactures bulk drugs. The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix.

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

FAQs for the comparison of Neuland Laboratories Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Neuland Laboratories Ltd or Senores Pharmaceuticals Ltd?

Market cap of Neuland Laboratories Ltd is 22,038 Cr while Market cap of Senores Pharmaceuticals Ltd is 5,946 Cr

What are the key factors driving the stock performance of Neuland Laboratories Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Neuland Laboratories Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Neuland Laboratories Ltd and Senores Pharmaceuticals Ltd?

As of June 14, 2026, the Neuland Laboratories Ltd stock price is INR ₹17177.5. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹1291.25.

How do dividend payouts of Neuland Laboratories Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Neuland Laboratories Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.